Exploring Cancer Biomarker Testing (CME)

Precision Medicine for Your Practice is a series of short (20-30 min), online modules covering specific topics in genomics and precision medicine. In this module, Exploring Cancer Biomarker Testing, participants will learn about large panel biomarker tests, which test for dozens or hundreds of genomic variants and other biomarkers that may be driving cancer growth and may be targetable with treatment.  Learn about benefits, limitations, and challenges of using large panel biomarker tests using the five parts of this module: an animated video providing overview information; practice cases to facilitate learning-by-doing; "dig deeper" for more in-depth topics; and logistics and additional resources for more detail.

To claim credit, follow the steps in the learning path.

CME Information and Disclosures

Activity Overview
Precision Medicine for Your Practice: Exploring Cancer Biomarker Testing (CME)

Original Publication Date:  December 20, 2016
Renewal Dates: December 12, 2019, November 17, 2022, May 25, 2023
Expiration Date: May 25, 2026

Learning Objectives
Upon completion of this educational activity, the learner will be able to:

• Determine the appropriate use of biomarker testing
• Assess the implications of biomarker testing results for treatment decisions
• Compare treatment options based on biomarker testing results

Target Audience
This activity is designed to meet the educational needs of practicing physicians who provide oncology care.

Accreditation Statement
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

In order to claim credit 1) answer the pre-assessment questions, 2) work through the module content in its entirety, 3) successfully complete the post-assessment answering 4 out of 5 questions correctly and 4) complete the evaluation.  

Credit Designation Statement
The American Medical Association designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Multimedia Contributors

• Emily Edelman, MS, CGC, Director, Clinical Education, The Jackson Laboratory
• Therese Ingram, MA, Associate Director and Senior Instructional Designer/Technologist, Clinical Education, The Jackson Laboratory
• Kalisi Logan, MS, CGC, Clinical Genomic Educator, Clinical Education, The Jackson Laboratory
• Laura Nicholson, MD, PhD, Director of Research, Graduate Medical Education (GME), Scripps Health
• Kate Reed, MPH, ScM, CGC, Director, Precision Oncology Education, Clinical Education, The Jackson Laboratory
• Linda Steinmark, MS, CGC,Project Manager, Clinical Education, The Jackson Laboratory

Disclosure Statement
Unless noted, all individuals in control of content reported no relevant financial relationships.

The following disclosures are reported that could be perceived as a real or apparent conflict of interest in the education program:

Kalisi Logan, MS, CGC, advisor for Igentify. Ms. Logan's contributions were peer reviewed by non-conflicted team members and modified as needed according to the results for the review to remove any identified commercial bias. 

References

Chakravarty, D., Johnson, A., Sklar, J., et al. (2022). Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol, 40(11), 1231-1258.

Chan, H. T., Chin, Y. M., & Low, S. K. (2022). Circulating Tumor DNA-Based Genomic Profiling Assays in Adult Solid Tumors for Precision Oncology: Recent Advancements and Future Challenges. Cancers (Basel), 14(13).

Bristol-Myer Squibbs. (2023). Opdivo (nivolumab) v. 2/23 [package insert]. Retrieved 5/8/23.

Cristescu, R., Aurora-Garg, D., Albright, A., Xu, et al. (2022). Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors. J Immunother Cancer, 10(1).

El-Deiry, W. S., Goldberg, R. M., Lenz, H. J., et al. (2019). The current state of molecular testing in the treatment of patients with solid tumors, 2019. CA Cancer J Clin, 69(4), 305-343.

Freedman, A. N., Klabunde, C. N., Wiant, K., et al. (2018). Use of Next-Generation Sequencing Tests to Guide Cancer Treatment: Results From a Nationally Representative Survey of Oncologists in the United States. JCO Precis Oncol, 2.

Frugtniet, B., Morgan, S., Murray, A., et al. (2022). The detection of germline and somatic BRCA1/2 genetic variants through parallel testing of patients with high-grade serous ovarian cancer: a national retrospective audit. BJOG, 129(3), 433-442.

George, A., & Turnbull, C. (2021). Tumor-only sequencing for oncology management: Germline-focused analysis and implications. Genes Chromosomes Cancer, 60(5), 352-357.

Li, M. M., Datto, M., Duncavage, et al. (2017). Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn, 19(1), 4-23.

Mandelker, D., Donoghue, M., Talukdar, S., et al. (2019). Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group. Ann Oncol, 30(8), 1221-1231.

Marabelle, A., Fakih, M., Lopez, J., et al. (2020). Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol, 21(10), 1353-1365.

Marrone, M., Filipski, K. K., Gillanders, et al. (2014). Multi-marker Solid Tumor Panels Using Next-generation Sequencing to Direct Molecularly Targeted Therapies. PLoS Curr, 6.

Morganti, S., Tarantino, P., Ferraro, E., et al. (2019). Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life. Crit Rev Oncol Hematol, 133, 171-182.

National Comprehensive Cancer Network. (2022). NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer, Including Fallopian Tube Cancer and Primary Peritoneal Cancer, v1.2023. Retrieved 4/26/23.

National Comprehensive Cancer Network. (2022). NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma, v2.2022, Retrieved 4/27/23.

National Comprehensive Cancer Network. (2022). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer, v1.2023. Retrieved 4/27/23.

National Comprehensive Cancer Network. (2023). NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms, v.2.2023. Retrieved 5/8/23.

Pinheiro, A. P. M., Pocock, R. H., Switchenko, J. M., Dixon, M. D., Shaib, W. L., Ramalingam, S. S., & Pentz, R. D. (2017). Discussing molecular testing in oncology care: Comparing patient and physician information preferences. Cancer, 123(9.

Tang, Y., Hu, X., Wu, K., & Li, X. (2022). Immune landscape and immunotherapy for penile cancer. Front Immunol, 13, 1055235.

Hardware/Software Requirements
Audio speakers or headphones
Screen resolution of 800X600 or higher
Adobe Reader 5.0 or higher 

Check the supported browsers.

Should you have technical questions or questions regarding the content of the activity, please email Clinical Education at the Jackson Laboratory.

Disclaimer 
All information in Precision Medicine for Your Practice is provided for educational purposes only. This information is not a substitute for clinical guidance or the consultation of a medical professional. Always seek the advice of a qualified health professional with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in Precision Medicine for Your Practice. Reliance on any information in Precision Medicine for Your Practice is solely at your own risk. The Jackson Laboratory does not endorse or recommend any specific procedures, tests, products, services, health professionals or other information that may be found in Precision Medicine for Your Practice.